Skip to content

Identification the Cause of Cerebral Infarction in Patients With Cancer

Identification the Cause of Cerebral Infarction in Patients With Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02212496
Enrollment
118
Registered
2014-08-08
Start date
2014-08-31
Completion date
2018-03-31
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Cancer, Cryptogenic Embolic Stroke

Brief summary

Although there has been increasing interest in the association between cancer and cerebrovascular disease, the underlying pathophysiology of stroke in cancer patients is still not fully understood. The aim of this study is to investigate the stroke mechanisms in patients with cancer-associated stroke.

Detailed description

Patients with cryptogenic embolic stroke will be prospectively enrolled and categorized into two groups according to the presence of active cancer: cryptogenic embolic stroke with active cancer (cancer-associated stroke) vs. without active cancer (cryptogenic embolic stroke). All patients will undergo brain MRI/MRA, 12-lead electrocardiography, transthoracic and transesophageal echocardiography with injection of agitated saline, and 24-hour Holter and/or telemonitoring. Duplex ultrasonography to detect venous thrombosis of the lower extremity will also be performed in patients with a positive right-to-left shunt on echocardiography.

Interventions

None listed

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects with acute ischemic stroke who presented within 7 days from symptom onset * Subjects who had embolic infarction outside the perforator territory revealed by diffusion-weighted imaging * Subjects with undetermined cause of stroke despite of initial evaluation including electrocardiogram and brain imaging upon admission * Subjects who performed brain magnetic resonance image (MRI) and MR angiography (MRA), cardiac work-ups (12-lead electrocardiography, transthoracic and/or transesophageal echocardiography with injection of agitated saline (or agitated saline transcranial Doppler monitoring), and 24-hour Holter and/or telemonitoring) * Subjects with informed consent

Exclusion criteria

* Subjects with single subcortical infarction * Subjects with primary brain tumor * Inability to perform comprehensive studies * Refusal or withdrawal of the consent

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of deep vein thrombosis and microembolic signal in cancer related stroke patientsWithin one week after enrollmentVenous thromboembolism was investigated via Doppler sonography and/or computed tomography pulmonary angiography combined with venous phase CT angiography of the lower extremities. Microembolic signal was detected via transcranial Doppler sonography on symptomatic cerebral circulation

Secondary

MeasureTime frameDescription
Impact of intravascular thrombosis on infarct volumeWithin one week after enrollmentInfarct volume was measured by diffusion-weighted MR imaging and apparent diffusion coefficient calculated from imaging data. Univariate and multivariate linear regression was performed in ESUS patients with cancer (adjusted for age, sex, overt DIC).
Impact of intravascular thrombosis on survivalTill the event of death occurs in enrolled patientsSurvival time (in years) was measured by subtracting admission date from the date the patient had expired. Cox proportional hazard analysis was used to evaluate association between intravascular thrombosis and survival (adjusted for age, sex, NIHSS, presence of overt DIC, infarct volume, metastasis, and histologic type).

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026